Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 6 of 6 for:    Open Studies | "Proctitis"

Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by University College London Hospitals.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University College London Hospitals
ClinicalTrials.gov Identifier:
NCT01414517
First received: August 10, 2011
Last updated: NA
Last verified: August 2010
History: No changes posted
  Purpose

The study will consist of pair of double-blind placebo-controlled trials of dietary supplementation with 15g/day FructoOligoSaccharide (FOS) for 7.5 weeks in patients with prostate carcinoma or 5 weeks in patients with cervical or endometrial carcinoma who are to undergo pelvic radiotherapy with intent to cure.


Condition Intervention Phase
Radiation Enteritis
Radiation Proctitis
Dietary Supplement: FructoOligoSaccharide
Dietary Supplement: Maltodextrin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy.

Resource links provided by NLM:


Further study details as provided by University College London Hospitals:

Primary Outcome Measures:
  • Gastrointestinal Status [ Time Frame: 5 weeks or 7.5 weeks ] [ Designated as safety issue: No ]
    To determine whether there is a difference in gastrointestinal status at 5 weeks (enumerated through the Birmingham score) in patients undergoing pelvic irradiation for gynaecological malignancy or at 7.5 weeks in patients undergoing radiotherapy for prostate malignancy given a prebiotic enhanced diet and those on placebo.


Secondary Outcome Measures:
  • Short Term Toxicity [ Time Frame: 5 weeks or 7.5 weeks ] [ Designated as safety issue: No ]
    To determine the effects of FOS on the short-term toxicity of pelvic irradiation (in comparison to placebo).

  • See Effects of FOS [ Time Frame: 5 or 7.5 weeks, 6 months ] [ Designated as safety issue: No ]
    To establish the effects of FOS on intestinal integrity, determined endoscopically, biochemically and histologically, after pelvic irradiation, both immediately and at 6 months follow-up

  • Effect of FOS on Chronic Radiation Bowel Disease [ Time Frame: 5 weeks or 7.5 weeks, 3 months, 6 months ] [ Designated as safety issue: No ]
    To provide pilot data to determine whether FOS given during pelvic irradiation has an effect on the risk of clinically apparent chronic radiation bowel disease.

  • Effect on Gut Microbiota [ Time Frame: 5 weeks or 7.5 weeks, 3 months, 6 months ] [ Designated as safety issue: No ]
    To confirm using fluorescence in-situ hybridization (FISH) the changes in the gut microbiota in patients on FOS enhanced diet in comparison with standard diet.


Estimated Enrollment: 220
Study Start Date: August 2010
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: FOS
Prebiotic (FructoOligoSaccharide-FOS.
Dietary Supplement: FructoOligoSaccharide
A mixture of 70% oligofructose and 30% inulin.
Placebo Comparator: Placebo
Maltodextrin (non-prebiotic carbohydrate).
Dietary Supplement: Maltodextrin
a non-prebiotic carbohydrate

Detailed Description:

The study will consist of pair of double-blind placebo-controlled trials of dietary supplementation with 15g/day FructoOligoSaccharide (FOS) for 7.5 weeks in patients with prostate carcinoma or 5 weeks in patients with cervical/endometrial carcinoma who are to undergo pelvic radiotherapy with intent to cure. Patients having post-operative adjuvant irradiation will be eligible, but not those having purely palliative treatment for symptom control. The clinical trials will be based at University College Hospital. Patients will attend a screening visit, a baseline visit, and follow-up visits at completion of radiotherapy, and then at three and six months.

Patients will be randomised to take a daily dietary supplement of either placebo (a non-prebiotic carbohydrate) or FOS (a mixture of 70% oligofructose and 30% inulin), provided as a single 15g sachet that can be dissolved in water or added to food. Randomisation in the gynaecological trial will be stratified according to diagnosis. In other respects management will be that offered routinely to patients undergoing pelvic radiotherapy for prostate malignancy or endometrial/cervical malignancy.

The studies are powered to detect the primary outcome measure of a clinical response (lower frequency of acute radiation enteritis/proctitis at 5 or 7.5 weeks respectively) using a 2-sample binomial arcsine where the predicted rate of acute radiation induced bowel disease when on FOS is 50% and 80% on placebo, to a significance of 0.05 and at a power of 90%.

Fifty-one patients will be required in each group to detect a significant difference between FOS and placebo. Therefore 110 patients will be recruited to each of the two studies to allow for attrition.

The primary endpoint will be the clinical gastrointestinal status at 7.5 weeks or 5 weeks at completion of radiotherapy. This status will be enumerated in comparison with placebo treated patients from the Birmingham score of intestinal symptoms (a simple clinical score from 0-15, usually employed in ulcerative colitis). Most patients commencing radiotherapy for these malignancies will have a pre-treatment score of zero or 1. A score of 4 or more is indicative of active coloproctitis, and differences of more than 2 points are to be considered clinically meaningful.

Secondary clinical endpoints will include the quantity of anti-diarrhoeal medication required, the international harmonised criteria for radiation toxicity, the EuroQol score of quality of life, and the appearance of the rectal mucosa: as judged endoscopically using the Baron score (a 0-3 scale usually employed in ulcerative colitis); and semi-quantitatively from histological assessment.

The Birmingham score and each of the clinical secondary endpoints will be assessed again at 3 and 6 months after completion of the radiotherapy. Endoscopic and histological assessment will be repeated only at 6 months after completion of radiotherapy.

Laboratory endpoints will include the measurement of short chain fatty acids (SCFA) (including butyrate) in faeces at baseline and at completion of radiotherapy, and study of the microbiota profile in the mucosa as determined by fluorescence in-situ hybridization (FISH). Haematological and biochemical parameters will be monitored as in standard practice.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The study group will comprise men and women aged 18 years or older with a histologically proven diagnosis of carcinoma of the prostate or carcinoma of the cervix or endometrium in whom radical radiotherapy has been selected in their treatment plan following assessment by the prostate oncology or gynecological oncology multidisciplinary team

Exclusion Criteria:

  • Exclusion criteria will preclude the recruitment of those having radiotherapy for purely palliative reasons. Patients known to have a current infection with an enteric pathogen, or who have used antibiotics within the past month, consumed any probiotic or prebiotic within the last month, or used any rectal/topical therapy within the last month will also be ineligible. Those known or suspected to have inflammatory bowel disease (ulcerative colitis or Crohn's disease) will be ineligible. Patients requiring hospitalisation, and those considered by the chief investigator (CI) to have important hepatic, renal, endocrine, respiratory, neurological or cardiovascular disease will also be ineligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01414517

Contacts
Contact: Alastair Forbes, MD;FRCP;FHEA 0845 1555 000 ext 9011 a.forbes@ucl.ac.uk

Locations
United Kingdom
University College London Hospital Recruiting
London, United Kingdom, NW1 2BU
Contact: Adeel Hamad, M.B.B.S    0845 1555 000 ext 9011    adeelhamad@msn.com   
Sponsors and Collaborators
University College London Hospitals
Investigators
Principal Investigator: Alastair Forbes, Bsc;MD;FRCP;FHEA University College London Hospitals/University College London
  More Information

No publications provided

Responsible Party: Alastair Forbes Prof., University College London Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT01414517     History of Changes
Other Study ID Numbers: 09/H0715/61
Study First Received: August 10, 2011
Last Updated: August 10, 2011
Health Authority: University College London Hospitals NHS Foundation Trust Research & Development Department, London, United Kingdom:

Keywords provided by University College London Hospitals:
Prebiotics
Acute Intestinal Injury
Chronic radiation enteritis

Additional relevant MeSH terms:
Enteritis
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on November 20, 2014